These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22161357)

  • 1. Early patient stratification and predictive biomarkers in drug discovery and development: a case study of ulcerative colitis anti-TNF therapy.
    Laifenfeld D; Drubin DA; Catlett NL; Park JS; Van Hooser AA; Frushour BP; de Graaf D; Fryburg DA; Deehan R
    Adv Exp Med Biol; 2012; 736():645-53. PubMed ID: 22161357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis.
    De Vos M; Dewit O; D'Haens G; Baert F; Fontaine F; Vermeire S; Franchimont D; Moreels T; Staessen D; Terriere L; Vander Cruyssen B; Louis E;
    J Crohns Colitis; 2012 Jun; 6(5):557-62. PubMed ID: 22398050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of Tenascin C.
    Magnusson MK; Strid H; Isaksson S; Bajor A; Lasson A; Ung KA; Öhman L
    J Crohns Colitis; 2015 Jan; 9(1):56-65. PubMed ID: 25518051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome.
    García-Bosch O; Gisbert JP; Cañas-Ventura A; Merino O; Cabriada JL; García-Sánchez V; Gutiérrez A; Nos P; Peñalva M; Hinojosa J; García-Planella E; Muñoz F; Calvet X; Panés J
    J Crohns Colitis; 2013 Oct; 7(9):717-22. PubMed ID: 23142005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.
    Su C; Salzberg BA; Lewis JD; Deren JJ; Kornbluth A; Katzka DA; Stein RB; Adler DR; Lichtenstein GR
    Am J Gastroenterol; 2002 Oct; 97(10):2577-84. PubMed ID: 12385442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort.
    Hiroz P; Vavricka SR; Fournier N; Safroneeva E; Pittet V; Rogler G; Schoepfer AM;
    Scand J Gastroenterol; 2014 Oct; 49(10):1207-18. PubMed ID: 25120029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study.
    Lee KM; Jeen YT; Cho JY; Lee CK; Koo JS; Park DI; Im JP; Park SJ; Kim YS; Kim TO; Lee SH; Jang BI; Kim JW; Park YS; Kim ES; Choi CH; Kim HJ;
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1829-33. PubMed ID: 23829336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment.
    Marits P; Landucci L; Sundin U; Davidsdottir L; Nilsson J; Befrits R; Wikström AC; Eberhardson M
    J Crohns Colitis; 2014 Aug; 8(8):881-9. PubMed ID: 24486178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.
    Arijs I; Li K; Toedter G; Quintens R; Van Lommel L; Van Steen K; Leemans P; De Hertogh G; Lemaire K; Ferrante M; Schnitzler F; Thorrez L; Ma K; Song XY; Marano C; Van Assche G; Vermeire S; Geboes K; Schuit F; Baribaud F; Rutgeerts P
    Gut; 2009 Dec; 58(12):1612-9. PubMed ID: 19700435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab for the treatment of pediatric ulcerative colitis.
    Bradley GM; Oliva-Hemker M
    Expert Rev Gastroenterol Hepatol; 2012 Dec; 6(6):659-65. PubMed ID: 23237250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on idiopathic colitides.
    Strobel S; Abreu MT
    Curr Opin Gastroenterol; 2013 Jan; 29(1):60-5. PubMed ID: 23207597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus.
    Tsukamoto H; Tanida S; Mizoshita T; Ozeki K; Ebi M; Shimura T; Mori Y; Kataoka H; Kamiya T; Joh T
    Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):714-8. PubMed ID: 23411870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.
    Panaccione R; Ghosh S; Middleton S; Márquez JR; Scott BB; Flint L; van Hoogstraten HJ; Chen AC; Zheng H; Danese S; Rutgeerts P
    Gastroenterology; 2014 Feb; 146(2):392-400.e3. PubMed ID: 24512909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents.
    Papa A; Felice C; Marzo M; Andrisani G; Armuzzi A; Covino M; Mocci G; Pugliese D; De Vitis I; Gasbarrini A; Rapaccini GL; Guidi L
    J Crohns Colitis; 2013 Mar; 7(2):113-9. PubMed ID: 22464811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of linear IgA bullous disease with ulcerative colitis: a case of successful treatment with infliximab.
    Yamada S; Makino T; Jinnin M; Sakai K; Fukushima S; Inoue Y; Ihn H
    Dermatology; 2013; 227(4):295-8. PubMed ID: 24281360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery.
    Andrisani G; Guidi L; Papa A; Potenza AE; Cervelli D; Armuzzi A
    J Crohns Colitis; 2013 Jun; 7(5):421-6. PubMed ID: 22889645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
    Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
    J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life and disability in patients with ulcerative colitis and proctocolectomy with ileoanal pouch versus treatment with anti-TNF agents.
    Meijs S; Gardenbroek TJ; Sprangers MA; Bemelman WA; Buskens CJ; D'Haens GR; Löwenberg M
    J Crohns Colitis; 2014 Jul; 8(7):686-92. PubMed ID: 24418659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.